Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of ZED1227 in well-controlled celiac disease with gluten challenge
2017-002241-30Phase 2Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ZED1227 in celiac disease (4 arms), sponsored by Dr. Falk Pharma GmbH. Started Dec 2017; status: completed.
02
Drugs
ZED1227
03
Conditions
celiac disease
Beyond the preview
Go deeper on 2017-002241-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002241-30.